At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
PNT2258drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating PNT2258 for Lymphoma, Diffuse Large B-Cell. Completed, enrolled 45 participants across 27 sites in 2 countries.
Detailed Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Diffuse Large B-Cell
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartDec 2014
Primary CompletionJul 2016
Study CompletionAug 2018
TodayJul 2026
First PostedAug 27, 2014
Enrollment StartDec 1, 2014
Primary CompletionJul 11, 2016
Study CompletionAug 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.8 years ago
Interventions
PNT2258drug